FDA approves Eli Lilly's Jaypirca as first-line treatment for CLL
The FDA approved Eli Lilly's drug Jaypirca as a first-line treatment for chronic lymphocytic leukemia (CLL) at a national level. The available details do not specify whether this is a full or accelerated approval.
Why it matters
This gives patients with CLL a new initial treatment option, addressing the need for more first-line therapies.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news